Sensai
Reading the tape…Pulling live market data…Setting the scene…
Sensai
AI Stock Dissection
AI Stock Dissection
MANKIND
Mr. Sheetal Arora · New Delhi, India · 20,451 employees
₹2,592.70
▼-0.96%Mankind Pharma is trading near its 52-week high with a premium valuation, reflecting strong investor confidence in its specialty generic drug portfolio and growth prospects.
Exchange
NSI
Currency
INR
Day range
₹2,583.00 – ₹2,642.00
52-week range
₹1,909.70 – ₹2,674.00
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
AI investment rating
AI analysis75% confidence
The stock appears fairly valued at current levels given its premium P/E ratio, though justified by strong growth and market positioning in high-demand therapeutic segments.
3.0% below the 1-year high · trend down
Hedge-fund memo
Today
The stock is down marginally (-0.96%) today but holding near its 52-week high, suggesting underlying strength despite minor profit booking.
This week
The stock has maintained resilience near its 52-week high, indicating continued positive sentiment among investors.
This month
The stock has been trading in an elevated range, consolidating near its yearly highs after a strong run-up.
Bull thesis
Bear thesis
News & sentiment
Neutral
24 headlines · 21 outlets · 7d
Tone · daily average
Smart money
Named holders aren't published for this listing (common for Indian stocks). The split at left is live.
Financial health
Profitability
Growth
Balance sheet
Financial statements
Earnings intelligence
Beat estimates in 2 of 4 recent quarters (EPS actual vs. consensus).
13.8855 vs 9.9
40.26% surprise
11.9871 vs 11.92857
0.49% surprise
12.38 vs 12.43333
-0.43% surprise
Competitive landscape
| Company | Market cap | P/E | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| MANKIND | 1.07T | 55.95 | 12.45% | 23.08% | 11.80% |
| ZYDUSLIFE | 1.11T | 22.27 | 18.32% | 18.97% | 16.20% |
| MEDANTA | 380.61B | 68.66 | 15.03% |
Technical intelligence
Volume
RSI (14) · 70 overbought / 30 oversold
MACD (12,26,9) · MACD vs signal
Candlesticks, volume, RSI and MACD from 498sessions of real Yahoo daily data. Moving averages use full history, so they're accurate at the left edge. Support / resistance are the 52-week low / high. Educational — technical signals are not buy or sell calls.
Risk intelligence
Increased competition in generic drug segments leading to pricing pressure
Mitigation: Focus on specialty formulations with less competition and higher margins
Regulatory challenges in international markets
Mitigation: Diversify geographic presence and strengthen compliance frameworks
Business intelligence
Competitive moat
Mankind Pharma possesses a strong competitive moat through its established brand presence in high-demand therapeutic segments, particularly sexual wellness, and a robust distribution network across India.
Supply chain
Upstream (inputs / suppliers)
↓
Downstream (customers / markets)
M&A / strategic moves
Catalyst calendar
Launch of new products in sexual wellness and dermatology segments
Expansion in regulated markets like US and Europe
Thesis builder
Bull case
Continued expansion in domestic and international markets, with successful launches in new therapeutic areas driving revenue growth beyond 10% annually.
Base case
Stable growth of 8-10% YoY with margin expansion through operational efficiencies and portfolio optimization.
Bear case
Regulatory hurdles in key export markets and increased competition in generic segments could pressure margins and growth.
Time horizon
3-5 years
Est. CAGR
8-12%
Entry (qual.)
The stock is trading near its 52-week high, but any pullback to the 2300-2400 range could present a better entry point for new investors.
Exit (qual.)
Consider trimming positions if the stock moves beyond 3000 INR without corresponding improvement in fundamentals, or if growth falls below 8% for consecutive quarters.
Knowledge graph
Executives & sector are live; peers are clickable → their dissection. Institutional holders shown where the exchange publishes them.
Portfolio impact
Enter tickers + weights, then see how MANKIND fits.
Scenario simulator
Simulate a macro shock and see the illustrative impact:
Tailwind for tech & enablers.
Illustrative impact
Medium prob.Directional illustration only — not modelled on this company's actuals. A real simulator needs company financials.
Explain like…
Re-explain MANKIND for a different audience:
Pick a persona to get a tailored explanation.
Sensai publishes educational market commentary, not investment advice. We are not SEBI-registered investment advisers or research analysts, and nothing here is a recommendation to buy, sell, or hold any security.
Live prices, index levels, and other market data are pulled from third-party feeds, may be delayed, and can be inaccurate or unavailable. Do not rely on them for trading decisions.
Investing in equities carries risk, including the loss of principal. Always do your own research and consider consulting a SEBI-registered adviser before making any investment decision.
Hidden risks
Hidden opportunities
Watch next
The stock remains attractive for long-term investors despite its premium valuation, given its strong market position in high-growth therapeutic segments.
UNILAD Tech·1d ago·unrelated to pharma
Collider·1d ago·popular sci-fi series
MarketsMojo·1d ago·trading interest surge
MarketsMojo·1d ago·trading interest surge
Yahoo Finance·1d ago·apparel company
CNBC TV18·1d ago·analyst positive view
livemint.com·1d ago·stock recommendation
movie.trueid.net·2d ago·sci-fi series
MakeUseOf·2d ago·sci-fi comparison
The European Times·2d ago·unrelated to pharma
AajTak·2d ago·founder success story
Mshale·2d ago·unrelated to pharma
Tribute Archive·2d ago·unrelated to pharma
Mshale·2d ago·unrelated to pharma
scanx.trade·3d ago·asset sale completed
The Economic Times·3d ago·positive drug outlook
ScreenRant·3d ago·sci-fi series
The Times of Israel·3d ago·unrelated to pharma
Oncodaily·3d ago·unrelated to pharma
ScreenRant·4d ago·sci-fi series
eWrestlingNews.com·4d ago·negative PR event
Daily Mail·4d ago·unrelated to pharma
bgr.com·4d ago·sci-fi recommendation
Real press coverage from the last 7 days, scored by AI for tone — click any headline for the source. This is news sentiment, not social: X / Reddit / Telegram scoring needs a paid social provider. Educational only.
Annual income statement, oldest → newest. Live via Yahoo.
10.6 vs 11.11667
-4.65% surprise
| 15.29% |
| 24.50% |
| MAXHEALTH | 1.08T | 75.09 | 14.33% | 22.68% | 12.20% |
Peers via Yahoo's similarity graph, same-sector first; fundamentals live. Ask the AI copilot below for a qualitative head-to-head.
Support (day/52w low)
₹2,583.00
Resistance (day/52w high)
₹2,642.00
Volume
3,09,402
Trend
down
RSI (14)
63
MACD
bullish
MA cross
golden
50-day MA
₹2,466.34
200-day MA
₹2,265.20
vs 200-DMA
14.5%
RSI/MACD computed from 6 months of daily closes; moving averages from Yahoo. Options positioning still needs an options feed.
Overall conviction 75%